Nurix Therapeutics Presents Preclinical Data From Two Autoimmune And Inflammatory Disease Programs, NX-5948 And GS-6791, At ACR Convergence 2024
Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in sel ...